Similarly, NAFLD patients carrying CG or GG PNPLA3 genotypes (N = 126) compared with non-carriers (N = 92) showed, lower BMI (Padj = 0.001), lower TG levels (Padj = 0.001) and HOMAIR (Padj = 0.004) and higher AST levels (Padj < 0.001). The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.